ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Dec 20, 2022 12:00 JST
Source:
Novotech Health Holdings Pte Ltd
Novotech is Gold Sponsor at Biotech Showcase 2023
SYDNEY, AU, Dec 20, 2022 - (ACN Newswire) - Novotech, the Asia Pacific centered biotech specialist CRO is proud to be Gold Sponsor at Biotech Showcase 2023. Novotech CEO Dr. John Moller and experts from the Novotech US and Asia Pacific teams will be attending the conference.
Meetings can be scheduled via the PartneringOne portal.
https://informaconnect.com/biotech-showcase/partnering/
Novotech will share the Asia Pacific advantages for expedited clinical trials, where biotechs have access to Novotech's vast patient populations, strong local regulatory knowledge, extensive site and KOL networks, and reputation for data quality.
Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions in Asia Pacific delivering exclusive benefits for sponsors.
The latest industry research publication by GlobalData and Novotech found almost 50% of new trials globally have sites in Asia Pacific. According to the new publication titled "State of the Global Biotech Landscape: Where the Opportunities Lie", demand for Asia Pacific trial sites is strong with almost half of the more than 27,000 clinical trials initiated in 2021 having sites in Asia Pacific. The data shows almost 12,900 of the new trials had sites in Asia Pacific.
Download the report here
https://novotech-cro.com/whitepapers/state-global-biotech-landscape-where-opportunities-lie
The report also noted that the Asia Pacific region, which has more than 6,772 trial sites each with access to an average of 2,136 million people, has considerable underutilized capacity presenting an opportunity for growth in multinational trials in the region.
Novotech this month was awarded the Frost & Sullivan Company of the Year Award 2022 for Best Practices in the Asia-Pacific contract research organization industry. Novotech has been a recipient of the Frost & Sullivan Asia Pacific Best Practices awards since 2006.
Frost & Sullivan said: "Our approach involves the deployment of best practices and strategic analytics across a value chain. Against this backdrop, Frost & Sullivan recognizes Novotech for its valuable achievement. Novotech addresses the global drug development market's unmet needs with a strong leadership focus that incorporates client-centric strategies with best-practice implementation. From feasibility assessments to regulatory submission support, data management, medical monitoring, and project management, the company provides a 360-degree approach to drug development for its biotech clients."
Novotech also recently produced a new publication for biotechs considering China for their clinical research, and the relevant processes required for global regulatory approvals. The report details regulatory requirements for biotechs including NDA and IND processes as well as ex-US research guidance for a successful US FDA approval pathway. Novotech provides the relevant regulatory knowledge and drug development pathways specifically designed to support the US FDA approval process, avoiding delays and additional costs.
Download whitepaper here
https://novotech-cro.com/whitepapers/china-biotech-landscape-opportunities-china-and-path-usfda-approval
Novotech has also recently been benchmarked as a top 10 CRO among the world's leading CROs, is a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award.
About Novotech -
https://novotech-cro.com
Novotech is internationally recognized as the leading Asia Pacific centred contract research organization (CRO) with global execution capabilities. Novotech is a clinical CRO with labs, phase I facilities, and drug development consulting services. It has accumulated experience in over 3,700 pre-clinical and clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biopharmaceutical clients conducting clinical trials in Asia, the US and globally. Novotech has over 2500 staff working across our offices in 13 geographies. For more information visit
https://novotech-cro.com/contact
Media Contact
David James
E:
communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427
Source: Novotech Health Holdings Pte Ltd
Sectors: BioTech, Healthcare & Pharm, Clinical Trials
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
TOYOTA GAZOO Racing begins WRC title bid with a legendary challenge
Jan 17, 2025 19:53 JST
Mitsubishi Corporation and JOGMEC Announce Investment in eFuels provider Infinium
Jan 17, 2025 14:35 JST
NEC Listed on the World Index and Asia Pacific Index of Dow Jones Sustainability Indices (DJSI)
Jan 17, 2025 12:47 JST
Mitsubishi Power Reinforces Commitment to Saudi Arabia's Sustainable Energy Future at Saudi Aramco's IKTVA Forum 2025
Jan 16, 2025 16:56 JST
JCB and DOJO Partner to Help Cardmembers Enjoy a More Seamless Payment Experience
Jan 16, 2025 11:00 JST
MHI Delivers 60 Cars for the Nippori-Toneri Liner Model 330
Jan 15, 2025 16:38 JST
JCB and Taiwan Rakuten Card Launch New JCB Panda Card
Jan 15, 2025 15:00 JST
Fujitsu, Resona Bank and Saitama Resona Bank launch new web service to simplify home-buying process
Jan 15, 2025 13:13 JST
FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jan 15, 2025 10:03 JST
18th Asian Financial Forum wraps up successfully
Jan 14, 2025 20:56 JST
Honda Civic Hybrid Named 2025 North American Car of the Year, Making Civic the Most Honored Model in the History of the Award
Jan 13, 2025 17:07 JST
Galaxy Payroll: Driving Innovation in Human Resources Management
Jan 10, 2025 23:35 JST
Honda 2025 Motorsports Program Overview
Jan 10, 2025 20:26 JST
TOYOTA GAZOO Racing Exhibiting at Tokyo Auto Salon 2025
Jan 10, 2025 18:38 JST
Mazda Introduce the All-NEW "Mazda6" Battery EV in Europe
Jan 10, 2025 17:27 JST
JCB unveils a new e-book that empowers merchants and acquirers to harness growth drivers in the European region
Jan 10, 2025 12:00 JST
NEC and Biomy Partner to Develop and Expand AI-Based Analytical Platforms in the Digital Pathology Field
Jan 10, 2025 11:37 JST
Outlander PHEV Tops Canada's Plug-In Hybrid EV Sales in 2024
Jan 10, 2025 09:25 JST
Honda Presents World Premiere of Honda 0 Saloon and Honda 0 SUV Prototypes at CES 2025
Jan 08, 2025 17:32 JST
Honda and Renesas Sign Agreement to Develop High-Performance SoC for Software-Defined Vehicles
Jan 08, 2025 12:30 JST
More Latest Release >>
Related Release
The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar
February 15 2023 09:00 JST
Novotech Global Report: Robust Phase 1 Trial Growth Across Asia Pacific
February 10 2023 19:00 JST
Asia Pacific Cell & Gene Research Growing 50% Faster than ROW
February 03 2023 13:00 JST
Novotech Acquires US-based Drug Development Consulting Firm, CBR International
January 12 2023 15:00 JST
Novotech Acquires European CRO, Strengthens Global Operations
January 12 2023 15:00 JST
Data Shows 50% of New Trials Have Sites in Asia Pacific
December 15 2022 10:00 JST
Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials
December 06 2022 11:00 JST
Novotech Chairs BioCentury Summit Workshop on How to Build and Finance an East-West MRCT Strategy
November 11 2022 17:00 JST
Clinical Research Opportunities in China and the Path to USFDA Approval - Whitepaper
October 25 2022 18:00 JST
The Biotech Landscape Webinar: Market Trends, Priorities, Predictions, and Pathways to FDA Approval
October 17 2022 11:00 JST
More Press release >>